Evotec (EVO) announced that its Chief Operating Officer, Dr Craig Johnstone, will step down and leave the company effective December 31. Dr Johnstone joined Evotec in May 2012 as SVP Drug Discovery and Innovation Efficiency and in April 2015 was named President and Site Head, Evotec (France) SAS. Dr. Johnstone was appointed Global Head, Integrated Drug Discovery in January 2017 and became Chief Operating Officer and a member of the Management Board of Evotec on 01 January 2019. Prof. Dr Iris Low-Friedrich, Chairwoman of the Supervisory Board of Evotec, said: “In his 12-year tenure, Craig has been instrumental in shaping Evotec and Global Operations in particular. On behalf of Evotec’s Supervisory Board, I would like to express our sincere gratitude to Craig for his commitment to the Company over the past decade. We wish Craig success in his future endeavours.”
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EVO:
- Amazon invests $4B more in Anthropic, Gap reports Q3 beat: Morning Buzz
- Evotec takes notice of Halozyme withdrawal, convicted in standalone strategy
- Evotec falls 21% to $4.20 after Halozyme withdraws acquisition proposal
- Halozyme withdraws proposal to acquire Evotec
- Halozyme withdraws proposal to acquire Evotec for EUR 11.00 per share in cash
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
